Skip to main content

The United States Food and Drug Administration has granted Marshall Edwards, Inc. an investigative new drug (IND) indication for triphendiol (NV-196).

Triphendiol is a chemosensitizing agent that is thought to depolarize mitochrondria and downregulate XIAP. It has also demonstrated broad cytostatic and cytotoxic properties against human cancer cells in vitro.

The IND indication is for triphendiol to be used in combination with Gemzar® (gemcitabine) for the treatment of unresectable, locally advanced, or metastatic pancreatic and bile duct cancers. The IND will enable a Phase IB study of triphendiol to proceed.

Recommended Articles

veggies

Nutritional Needs during Cancer Treatment

Expert insight into eating well during cancer treatment

Liver

Treatment & Management of Liver Cancer

Surgery, liver directed therapies, immunotherapy and precision cancer medicines are used to treat liver cancers.